Compare AstraZeneca plc (AZN) vs iShares TIPS Bond ETF (TIP) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

TIP trades at $107.91, down 0.2% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The stock lacks key valuation metrics like P/E and P/S, and recent news highlights bond market volatility and Federal Reserve uncertainty influencing fixed-income assets. Dividend payments are scheduled for mid-2026, providing income visibility.

Outlook remains cautious due to technical weakness and macroeconomic pressures from potential Fed rate hikes. Risks include interest rate sensitivity and market sentiment shifts, while the dividend yield offers a defensive cushion. Investors should monitor earnings reports for fundamental clarity amid the bearish trend.